Thymosin Alpha-1 vs Chonluten
Side-by-side comparison of key properties, dosing, and research.
Immune SupportAnti-Aging & Longevity
Thymosin Alpha-1Anti-Aging & Longevity
Chonluten- Summary
- Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide derived from the thymus gland. It is a powerful immune modulator approved in many countries for treating chronic hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Half-Life
- 2–3 hours
- Short (minutes for the peptide); sustained gene-regulatory effects
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.8–1.6 mg
- 10 mg per day
- Frequency
- Twice weekly
- Daily for 10–30 days
- Key Benefits
- Enhances T-cell and NK cell activity
- Supports recovery from viral and bacterial infections
- May reduce inflammation systemically
- Supports healthy aging and immune resilience
- Improves vaccine response
- Supports liver health
- May help with chronic fatigue syndrome and post-viral conditions
- Approved in multiple countries for hepatitis B and C treatment
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Side Effects
- Injection site irritation
- Mild flu-like symptoms initially (immune activation)
- Fatigue (rare)
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- Stacks With
- —
- —